Press Release: Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.
LOS ANGELES, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period"). Allarity investors have until November 12, 2024 to file a lead plaintiff motion.
Press Release: Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion. - Newscast
Thu, 13 Mar 2025 11:29:00 GMT Allarity Therapeutics Inc. former executives concealed that the Food and Drug Administration wasn’t going to approve its key kidney cancer drug without more testing, the Securities and Exchange ...
Wed, 26 Feb 2025 05:00:00 GMT Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity ... formerly known under the names E7449 and 2X-121. This press release contains “forward-looking statements” within ...
Mon, 24 Feb 2025 05:00:00 GMT 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual ...
Mon, 24 Feb 2025 00:01:00 GMT About Allarity Therapeutics This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements ...
Thu, 13 Feb 2025 07:01:00 GMT NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the ...
